KROS
Keros Therapeutics Inc
$
13.730
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.750
Open
13.320
VWAP
13.46
Vol
716.80K
Mkt Cap
557.65M
Low
13.1944
Amount
9.65M
EV/EBITDA(TTM)
-88.27
Total Shares
36.08M
EV
-147.59M
EV/OCF(TTM)
-2.68
P/S(TTM)
2.29
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
0.00
-100%
-1.400
-138.67%
2.08M
-31.7%
-1.050
-7.89%
1.64M
+322.04%
-0.965
-31.56%
Estimates Revision
The market is revising Downward the revenue expectations for Keros Therapeutics, Inc. (KROS) for FY2025, with the revenue forecasts being adjusted by -0.48% over the past three months. During the same period, the stock price has changed by 0.59%.
Revenue Estimates for FY2025
Revise Downward
-0.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+42.68%
In Past 3 Month
Stock Price
Go Up
+0.59%
In Past 3 Month
10 Analyst Rating
76.04% Upside
Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 24.17 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
5 Hold
0 Sell
Moderate Buy
76.04% Upside
Current: 13.730
Low
15.00
Averages
24.17
High
35.00
76.04% Upside
Current: 13.730
Low
15.00
Averages
24.17
High
35.00
BofA
Jason Zemansky
Buy -> Neutral
downgrade
$32 -> $18
2025-06-10
Reason
BofA
Jason Zemansky
Price Target
$32 -> $18
2025-06-10
downgrade
Buy -> Neutral
Reason
BofA analyst Jason Zemansky downgraded Keros Therapeutics to Neutral from Buy with a price target of $18, down from $32. The company announced the conclusion of its strategic review, with the board opting to move forward with KER-065 for Duchenne muscular dystrophy and to return $375M in excess capital to shareholders, the analyst tells investors in a research note. The firm says the downgrade isn't an indictment of what it still thinks "is an intriguing" platform an pipeline. However, even acknowledging the stock's relative valuation and "downside protection" from its strong cash position, BofA suspects near-term share upside may be limited with key insights on 'KER-065 unlikely for some time and safety still an overhang. Investors will likely require more to re-engage at this point, contends the firm.
BofA
Jason Zemansky
Buy
maintain
$33 -> $32
2025-05-27
Reason
BofA
Jason Zemansky
Price Target
$33 -> $32
2025-05-27
maintain
Buy
Reason
BofA analyst Jason Zemansky lowered the firm's price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares. The firm notes frustrations from bulls, with shares trading absent much value for the Takeda (TAK) deal, but whether cibotercept and KER-065 are meaningful drags on sentiment or the P&L, as argued by activist ADAR1 Capital Management, is "less clear to us," the analyst tells investors.
Scotiabank
Outperform
to
NULL
downgrade
$41 -> $26
2025-05-12
Reason
Scotiabank
Price Target
$41 -> $26
2025-05-12
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Keros Therapeutics to $26 from $41 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors. The firm sees limited value-driving catalysts for the stock in the near-term.
H.C. Wainwright
Andrew Fein
Buy
downgrade
$40 -> $25
2025-05-08
Reason
H.C. Wainwright
Andrew Fein
Price Target
$40 -> $25
2025-05-08
downgrade
Buy
Reason
H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Keros Therapeutics to $25 from $40 and keeps a Buy rating on the shares. Th firm says the early termination of the TROPOS trial due to pericardial effusions across all dose cohorts "was a clear setback for cibotercept." However, the forthcoming dataset still matters, the analyst tells investors in a research note.
Truist Securities
Srikripa Devarakonda
Strong Buy
Maintains
$43 → $25
2025-04-09
Reason
Truist Securities
Srikripa Devarakonda
Price Target
$43 → $25
2025-04-09
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Keros Therapeutics to $25 from $43 and keeps a Buy rating on the shares as part of a broader research note on Biotech. Keros is an attractive company for investors with a longer-term horizon, particularly in the context of the current macro environment and uncertainty around Biopharma, and the stock is trading below cash, the analyst tells investors in a research note. The stock is undervalued with no value to any pipeline programs or even the partnered ones, though the firm is acknowledging investor skepticism given safety concerns, Truist adds.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$40
2025-04-01
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$40
2025-04-01
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Keros Therapeutics Inc (KROS.O) is -3.18, compared to its 5-year average forward P/E of -11.20. For a more detailed relative valuation and DCF analysis to assess Keros Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.20
Current PE
-3.18
Overvalued PE
-5.11
Undervalued PE
-17.28
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.51
Current EV/EBITDA
2.79
Overvalued EV/EBITDA
1.33
Undervalued EV/EBITDA
-6.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
17484.93
Current PS
54.89
Overvalued PS
87350.23
Undervalued PS
-52380.38
Financials
Annual
Quarterly
FY2025Q2
YoY :
+49002.70%
18.17M
Total Revenue
FY2025Q2
YoY :
-21.06%
-39.82M
Operating Profit
FY2025Q2
YoY :
-32.17%
-30.70M
Net Income after Tax
FY2025Q2
YoY :
-39.20%
-0.76
EPS - Diluted
FY2025Q2
YoY :
-24.35%
-30.34M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
22.80
FCF Margin - %
FY2025Q2
YoY :
-99.86%
-168.96
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
9.5M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
390.9K
Volume
1
6-9
Months
980.9K
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
1
2.6M
Volume
Months
3-6
0
0.0
Volume
Months
6-9
6
1.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
9.5M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KROS News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
06:02:58
Keros Therapeutics to discontinue cibotercept, announces COO departure
2025-07-17 (ET)
2025-07-17
08:05:32
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
2025-06-09 (ET)
2025-06-09
15:15:12
ADAR1 says Keros needs 'fresh perspectives in the boardroom'
Sign Up For More Events
Sign Up For More Events
News
9.0
07-17NASDAQ.COMKeros To Receive Milestone Payment Under License Agreement With Takeda
9.0
06-18ReutersFat, not muscle: drugmakers in race for next weight-loss breakthrough
6.0
06-10BenzingaKeros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
Sign Up For More News
People Also Watch
SAGE
SAGE Therapeutics Inc
0
USD
-0.23%
BIOX
Bioceres Crop Solutions Corp
3.100
USD
-6.63%
SVC
Service Properties Trust
2.280
USD
-7.69%
VBNK
Versabank
10.260
USD
-2.47%
ALNT
Allient Inc
42.000
USD
-0.67%
API
Agora Inc
3.830
USD
+1.59%
FC
Franklin Covey Co
18.850
USD
-1.05%
URGN
Urogen Pharma Ltd
17.745
USD
-4.55%
ESPR
Esperion Therapeutics Inc
1.870
USD
+3.31%
MYE
Myers Industries Inc
15.840
USD
+0.13%
FAQ
What is Keros Therapeutics Inc (KROS) stock price today?
The current price of KROS is 13.73 USD — it has increased 2.77 % in the last trading day.
What is Keros Therapeutics Inc (KROS)'s business?
What is the price predicton of KROS Stock?
What is Keros Therapeutics Inc (KROS)'s revenue for the last quarter?
What is Keros Therapeutics Inc (KROS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Keros Therapeutics Inc (KROS)'s fundamentals?
How many employees does Keros Therapeutics Inc (KROS). have?